Tazemetostat: Targeting EZH2 in R/R Follicular Lymphoma

October 14, 2023

By Brian T. Hill, MD, PhD
Jennifer L. Garson, PA-C

Opinion

Video

Hematologist/oncologists describe the rationale for treatment approaches targeting EZH2 and discuss recent guideline updates surrounding the role of tazemetostat and EZH2 testing in patients with follicular lymphoma.

EP: 1.Highlighting Mitigation Strategies for Toxicity in Follicular Lymphoma

EP: 2.The Evolution of the Treatment Landscape for Follicular Lymphoma

EP: 3.Patient Scenario 1: 65-Year-old Woman with R/R Follicular Lymphoma

EP: 4.Evolving Treatment Strategies for R/R Follicular Lymphoma

EP: 5.AUGMENT: Lenalidomide plus Rituximab in R/R Follicular Lymphoma

Now Viewing

EP: 6.Tazemetostat: Targeting EZH2 in R/R Follicular Lymphoma

EP: 7.Role of PI3K Inhibitors in R/R Follicular Lymphoma

EP: 8.Follow-up Monitoring Strategies in R/R Follicular Lymphoma

EP: 9.Patient Profile 2: R/R Follicular Lymphoma with Early Disease Progression

EP: 10.Role of CAR-T Therapy in R/R Follicular Lymphoma

EP: 11.Considerations and Challenges Surrounding CAR-T Therapy and Bispecifics

EP: 12.Strategies for AE Management with Bispecific Antibodies

EP: 13.Treatment Approaches for R/R Follicular Lymphoma in the 3L and Beyond

EP: 14.Expert Insight and Future Perspectives for Follicular Lymphoma

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!